What development phase is REGADENOSON ANHYDROUS in?

REGADENOSON ANHYDROUS is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

REGADENOSON ANHYDROUS

FDA-approved approved Small molecule Quality 0/100

Regadenoson Anhydrous is a marketed drug with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and revenue generation. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	REGADENOSON ANHYDROUS
Modality	Small molecule
Phase	FDA-approved
First approval	2008

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

REGADENOSON ANHYDROUS CI brief — competitive landscape report
REGADENOSON ANHYDROUS updates RSS · CI watch RSS